Mi az ára Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (HTBX) ára $2.38

Mi a Heat Biologics, Inc. (HTBX piaci tőkésítése)

Heat Biologics, Inc. piaci tőkésítése (HTBX) $61.07M

Heat Biologics, Inc. (HTBX) P/B mutató

Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Év	P/B arány	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

P/B arány

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	P/B arány	P/B arány különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

P/B arány

P/B arány különbség

Ország